Tucson, Ariz. – Researchers at the University of Arizona College of Medicine-Tucson and Dignity Health St. Joseph’s Hospital and Medical Center – Phoenix have come up with a new method for treating the decrease in body temperature that occurs under anesthesia during surgery (anesthesia-induced hypothermia). The team, which includes anesthesiologist Amol Patwardhan, M.D., Ph.D., working with Frank Porreca, Ph.D., of the University of Arizona, and Andrej Romanovsky, M.D., Ph.D. at St. Joseph’s, have been investigating the utility of TRPV-1 antagonists to address this condition.Continue reading→

Arizona State University announced today that Joshua LaBaer, a leading researcher in cancer and personalized medicine, has been appointed the new executive director of the Biodesign Institute at Arizona State University, effective April 1.Continue reading→

Life365, a digital health platform as a service provider, announced a partnership with Catalytic Health Partners, a population health management company that provides enhanced care to high cost Medicare and Medicaid populations in order to improve outcomes while reducing total cost of care.Continue reading→

PHOENIX (March 28, 2017) – Healthcare IT company Topaz Information Services has partnered with iTel Companies Inc., a telehealth company, to offer a seamless integration of telehealth services to its clients. Continue reading→

On March 27, 2017, Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”)  announced that, effective April 17, 2017, Saeed Motahari, will become the Company’s President and Chief Executive Officer (“CEO”) and be appointed to the Company’s Board of Directors.Continue reading→

WASHINGTON, D.C. – On March 22, 2017, Congresswoman Kyrsten Sinema (AZ-09) and Congressman Trey Hollingsworth (IN-09) introduced the Fostering Innovation Act, bipartisan legislation to provide commonsense regulatory relief for companies on the cutting edge of scientific and medical research.Continue reading→

On March 23, 2017, Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or the “Company”)  announced that the Drug Enforcement Agency (“DEA”) has issued an interim final rule that would result in Syndros™ (dronabinol oral solution) being placed in Schedule II of the Controlled Substances Act.  On July 1, 2016, the Food and Drug Administration (“FDA”) approved the New Drug Application for Syndros.Continue reading→

TUCSON, Ariz., March 22, 2017 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it has obtained CE marking in the European Union for its HTG EdgeSeq ALKPlus Assay EU.Continue reading→